Targeting IL-17 pathways with specific inhibitors or monoclonal antibodies may represent a promising therapeutic strategy for IPF, as demonstrated by emerging preclinical studies (112). This evidence concerns the gene IL17A and idiopathic pulmonary fibrosis.